Webinar Regarding Cellular Physiology - Spectra Research Corporation

The cancer world isn’t flat: why cancer researchers adopt 3-D bioprinting

The growing push for 3-D tissue models is limited by challenges in automated handling, processing and scalability of the technology to various types of materials and high-throughput applications. To meet these challenges, ROKIT Healthcare has developed all-in-one bioprinting platforms and human-cell derived ECM bioinks that allow researchers to biologically mimic the formation of complex, heterogeneous 3-D structures and to scale the technology to high-throughput applications. This webinar will focus on the platform’s usage in cancer biology. It will discuss evidence for 3-D bioprinting capturing altered proliferation and cell morphology profiles, revealing more realistic drug responses, and mimicking vascularized tumor microenvironments – to suggest why bioprinting of cancer cells is a scientifically rigorous method to generate physiologically relevant cancer models for preclinical screening and testing, as well as for new therapy research. You will learn about:
– Key advantages of 3D bioprinting over other techniques
– Five alterations in cellular physiology of cancer cells in 3D vs. 2D
– Evaluation of how 3D bioprinted tissues have altered proliferation and cell morphology
– Evaluation of how 3D bioprinted tissues reveal more realistic drug responses
– Evaluation of how 3D bioprinted tissues mimic complex tumor-immune microenvironments
– Built-in cell incubator, diverse material use, and high-throughput capabilities of ROKIT Healthcare’s all-in-one bioprinting platform Dr. INVIVO 4D6

Dr. Sanjay Gupta

Professor & Research Director

Dr. Sanjay Gupta is a Professor & Research Director and holds Carter Kissell Endowed Chair in Urologic Oncology in the Department of Urology at Case Western Reserve University and The Urology Institute at the University Hospitals Case Medical Center. Dr. Gupta’s research focuses on understanding the risk factors and mechanisms of prostatic and bladder diseases, develop appropriate biomarkers for early detection and prognosis, identify novel targets to monitor the efficacy of various synthetic and natural agents and develop them as chemo preventatives/therapeutics Dr. Gupta has authored some 150 publications, including book chapters, research articles and reviews, and has spoken at several occasions in cancer prevention symposium, seminars and meetings. He has been serving in various study sections at National Cancer Institute (NCI) and Department of Defense (DOD), and other councils around the globe.